Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To evaluate the efficacy and adverse reactions of Herceptin as a single agent in patients with HER2 overexpressing metastatic breast cancer.
Methods: There were two kinds of therapy protocol. One was loading-dose of 4 mg/kg intravenously, followed by a 2 mg/kg maintenance dose of weekly intervals. The other was loading-dose of 8 mg/kg, followed by 6 mg/kg of every three weeks intervals.
Results: Among 20 patients with evaluated efficacy, there was no complete response, 5 patients (25.0%) showed partial response (PR), 5 (25.0%) stable disease (SD) and 10 (50.0%) progressive disease (PD). Of 22 patients, the overall response rate was 22.7%. The median time of disease progression and treatment failure was 6 weeks and 6.5 weeks, respectively. The most common adverse reactions were fever and chill. Cardiac symptoms could be seen in some patients.
Conclusion: Herceptin is an active agent for the patients with HER2 overexpressing metastatic breast cancer and the adverse events are well tolerated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dopamine DR availability after discontinuation of antipsychotic treatment: a [C]raclopride PET study in remitted first-episode psychosis patients.
Psychol Med
September 2025
https://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.
Background: After remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D receptor (DR) antagonist and partial agonist antipsychotics on striatal dopamine DR availability in FEP patients.
Methods: Remitted FEP patients underwent two [C]raclopride PET scans to measure striatal DR availability: 1 week after antipsychotic discontinuation (n = 16 antagonist users, n = 6 partial agonist users) and after being medication free for 6-8 weeks (n = 8 antagonist users, n = 5 partial agonist users).
Enhancing Parkinson's and palliative patients' care: nurse perspectives on the Neria Guard infusion set.
Br J Nurs
September 2025
Senior Director Medical and Clinical Affairs, Convatec Technology Centre, Deeside, UK.
Background: The Neria™ Guard infusion set is indicated for the infusion of several medications for Parkinson's and pain-management therapy.
Aim: The aim of this study was to explore the impact of the Neria Guard infusion set on patients and health professionals from the perspective of nurses.
Method: Two surveys were distributed to nurses: one targeting nurses who use Neria Guard for Parkinson's patients, and one for those who use it for palliative care patients.
Treatment Persistence After Major Cardiovascular Events in Psoriasis: A Retrospective Cohort Study Comparing Biologic, Systemic, and Phototherapy.
J Dermatol
September 2025
Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea.
Patients with psoriasis experience significantly higher cardiovascular morbidity compared to the general population. Although certain psoriasis treatments may confer cardioprotective effects, current clinical guidelines addressing treatment continuation following major adverse cardiovascular events (MACE) are lacking. Therefore, we conducted a retrospective cohort study using Korean health insurance data (January 2008-October 2021) to examine treatment modifications after MACE in patients with psoriasis.
View Article and Find Full Text PDFMultimodal treatment approach with sunitinib, pembrolizumab, bevacizumab, sirolimus, and zoledronic acid for locally advanced clear cell renal cell carcinoma: a case report.
Croat Med J
August 2025
Mehrdad Payandeh, Internal Medicine Department, School of Medicine, Kermanshah University of Medical Sciences, Beheshti Blvd, 83VX+PCM, Kermanshah, Iran,
Locally advanced renal cell carcinoma (RCC) presents significant therapeutic challenges, particularly in resource-limited settings with restricted access to new therapies. This report describes a new exploratory multimodal therapeutic approach for a patient with locally advanced clear cell RCC (ccRCC) with adrenal and lymph node metastases. A 45-year-old woman presented with an incidentally discovered 9-cm mass in the left kidney, which was later diagnosed as grade-2 ccRCC with adrenal and lymph node involvement.
View Article and Find Full Text PDFThe Use of Plasma Exchange for Clozapine Intoxication: A Case Report.
Pharmacotherapy
September 2025
Department of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.
We describe a case of a 56-year-old male who developed severe, refractory hypotension after an intentional ingestion of clozapine and who became hemodynamically stable after one session of therapeutic plasma exchange (TPE). The patient, who presented after an ingestion of clozapine, was found to have altered mental status and hypotension in the emergency department. Escalating catecholamine vasoactive agents were necessary to maintain adequate hemodynamics.
View Article and Find Full Text PDF